Xanthine oxidase inhibitors in ischaemic heart disease

Mihnea Zdrenghea, Adela Sitar-Tăut, Gabriel Cismaru, Dumitru Zdrenghea, Dana Pop

Abstract

Increased uric acid levels are correlated with cardiovascular disease, particularly with ischaemic heart disease. Xanthine oxidase inhibitors, especially allopurinol, lower the risk of ischaemic heart disease due to their effects on reactive oxygen species and endothelial function. In chronic stable angina pectoris, allopurinol increases the median time to ST depression, time to chest pain, and total exercise time. On the other hand, it has been reported that allopurinol has a beneficial effect on ischaemic patients referred for angioplasty, but there are insufficient data regarding its effect on acute myocardial infarction patients. Moreover, other important actions of allopurinol are regression of left ventricular hypertrophy and improvement in the results of cardiac rehabilitation. The efficacy of allopurinol has recently been acknowledged by the European Society of Cardiology guidelines for stable angina pectoris, but the particular role of allopurinol in ischaemic heart disease patients is not fully established.

Keywords: xanthine oxidase inhibitors, ischaemic heart disease, uric acid

There are many cardiovascular conditions and risk factors associated with elevated uric acid levels. Uric acid favours hypertriglyceridaemia, being involved in the increase of liver protein synthesis and turnover. Hyperuricaemia has been associated with an increased incidence and prevalence of hypertension, stroke and carotid, peripheral and coronary atherosclerotic vascular disease. There is also a correlation between elevated levels of uric acid and inflammatory markers, including C-reactive protein (CRP), plasminogen activator inhibitor type I, and soluble intercellular adhesion molecule (ICAM). All these factors represent another possible link between uric acid and atherosclerosis, especially ischaemic heart disease. In a review on uric acid levels in cardiovascular disease, Kanbay et al. cite eight prospective studies based on medical and post mortem records, and coronary events registries, which demonstrate an increased risk of coronary heart disease in subjects with hyperuricaemia, with odd ratios (OR) between 1.12 and 2.30.

These data suggest that a decrease in serum uric acid level could be beneficial in patients either at risk for or with established ischaemic heart disease. The most commonly used drugs to decrease uric acid levels are inhibitors of xanthine oxidase (XO). This enzyme is involved in uric acid synthesis, in the production of superoxide radicals and, consequently, in atherosclerosis. Therefore, a decrease in its activity may have anti-atherogenic and anti-ischaemic effects. There are three clinically available XO inhibitors: allopurinol, oxyipurinol and febuxostat, the first being most widely used in clinical practice.

The many potential pharmacological cardiovascular benefits of XO inhibitors include improvement in endothelial function, decrease in tissue oxidative stress, increase in ATP synthesis in ischaemic tissue, and improvement in exercise-induced ischaemia. XO inhibitors may also be beneficial in prevention of primary cardiovascular disease, left ventricular hypertrophy, acute coronary syndrome, stroke and heart failure. We will briefly discuss the main areas in which XO inhibitors could be or have already proven useful.

Anti-atherogenic effects

The anti-atherogenic effects of XO inhibitors have mainly been studied in relation to endothelial function and oxidative stress parameters. Inflammatory markers and lipid profile have also been considered. XO represents a source of reactive oxygen species that results in both endothelial dysfunction and vascular inflammation. Consequently, lowering serum uric acid levels through XO inhibitors has anti-atherogenic effects.

A review and meta-analysis of 40 studies reports that circulating markers of oxidative stress, such as malonaldehyde, were significantly decreased by XO inhibitors in six of the studies. Other studies found that brachial artery flow-mediated dilatation was increased, with an OR of 2.50. The forearm blood flow response to acetylcholine infusion was increased by 60.68%.

In their 2013 review, Kanbay et al. analysed the relationship between reduction in uric acid level and improvement of
endothelial dysfunction in patients with diseases including congestive heart failure, the metabolic syndrome, diabetes and chronic kidney disease. In all cases, the improvement was significant, between 25 and 100%. On the other hand, studies on inflammation and lipid profile yielded controversial data. XO inhibitors did not influence CRP levels in several studies, CRP being decreased in only one. ICAM was also reduced in only one of the studies. Fibrinogen, interleukin 6 (IL-6), vascular endothelial growth factors (VEGF) and E-selectin levels were not affected. One study found an improved lipid profile, but two further studies did not.

Ziga et al. reported that in 40 hyperuricaemic patients, levels of triglycerides, total cholesterol, low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol were slightly increased after three months of allopurinol treatment. The authors suggested that in patients with the metabolic syndrome, lipid profile should be monitored after the initiation of allopurinol treatment, as the atherogenic index is increased in these patients. Remin and B-type natriuretic peptide (BNP) levels were decreased by XO inhibitors, this finding being of special relevance to ischaemic and heart failure patients.

**Angina pectoris**

The use of allopurinol improves chronic stable angina. Angina pectoris has a high prevalence of 5.7% in men and 6.7% in women, not all of them being referred for interventional cardiology. In these patients, allopurinol could be useful to increase exercise time, time to 1-mm ST depression, and time to angina. This is the main reason why allopurinol is recommended when classical anti-anginal drugs are contra-indicated or not efficient in controlling angina. The previous assertion is in agreement with the 2013 European Society of Cardiology guidelines on the management of stable coronary heart disease, which recommend 600 mg/day allopurinol under the ‘other drugs’ heading.

Allopurinol has been found to improve exercise capacity by increasing ATP production for the same myocardial oxygen supply. Therefore allopurinol increases not only exercise capacity, but also the double product and peak effort. On the other hand, classical anti-anginal drugs increase exercise capacity, but not the double product or myocardial energy production.

Other beneficial effects of allopurinol are related to endothelial function and coronary vasoconstriction. Rajendra et al. studied endothelial function assessed by forearm venous occlusion plethysmography, flow-mediated dilation and pulse-wave plethysmography in 80 patients with coronary heart disease. Compared to the placebo group, allopurinol improved endothelium-dependent vasodilation and completely eliminated oxidative stress.

In another study, Noman et al. investigated the effects of high-dose allopurinol on exercise in patients with stable angina pectoris. The study included 65 patients with positive stress testing, in whom 600 mg/day allopurinol increased time to ST depression from 232 to 298 seconds. The duration of exercise was consequently increased from 301 to 393 seconds. The time to chest pain was increased too, from 234 to 304 seconds, the difference being highly significant. On the contrary, the effect on the number of angina episodes/week or number of tablets of glyceryl trinitrate/week was not significant in comparison with placebo.

Unfortunately, there are further studies which do not confirm the aforementioned results. They describe no significant improvement of exercise capacity in patients with stable angina treated with allopurinol.

Rekraj et al. studied the effect of high-dose allopurinol on left ventricular hypertrophy and endothelial function in patients with chronic stable angina. Using 600 mg allopurinol daily, flow-mediated vasodilatation increased by 0.82 ± 1.8% at nine months, from 4.1 ± 2.1% at baseline. On the other hand, in the placebo group, the initial flow-mediated vasodilatation of 5.68% decreased by 0.69 ± 2.8% at nine months (p = 0.017). The data suggested the need for long-term treatment with allopurinol in order to obtain anti-atherosclerotic effects.

The same article showed a nine-month left ventricular mass (LVM) and left ventricular mass index (LVMII) decrease of 5.2 g and 2.2 g/m², respectively, in the allopurinol group, versus 1.3 g and 0.53 g/m² in the placebo group, the difference being highly significant. They also determined the augmentation index (AIX), which was lower in the allopurinol group, suggesting not only improvement in endothelial function, but also less vascular remodelling. The results suggest that allopurinol is useful in hypertensive patients with ischaemic heart disease.

Agarwal et al. recently presented a meta-analysis of 10 studies on the effects of allopurinol in 738 hypertensive patients. Compared to the control group, allopurinol-treated patients displayed a 3.3-mmHg systolic and a 1.3-mmHg diastolic blood pressure decrease.

**Other manifestations of ischaemic heart disease**

There are many further studies on the effects of allopurinol in ischaemic heart disease but data are insufficient to allow the formulation of strong evidence-based guidelines. Beneficial effects were reported mainly in patients with myocardial revascularisation with coronary artery bypass surgery or angioplasty post myocardial infarction.

Available data allow advocating a role for allopurinol in decreasing the number of complications, including arrhythmias, and improving myocardial function in revascularised patients, sustained by experimental data on the effect of allopurinol on cardiomyocyte apoptosis in rats after myocardial infarction. Xiao et al. reported a decrease in apoptosis measured through caspase activity in non-infarcted myocardial areas in rats with infarction. The study suggests myocardial protection through allopurinol, not only in chronic forms of ischaemic heart disease, but also in acute coronary syndromes.

In 2010, Rentoukas et al. reported that acute myocardial infarction patients submitted to primary percutaneous angioplasty and treated with a loading dose of 400 mg allopurinol followed by 100 mg daily for one month displayed a more effective ST-elevation recovery and lower peak values of troponin, CK-MB and creatine phosphokinase (CPK), along with a 13% decrease in major adverse cardiac effects at one-month follow up.

In a recent review, Grimaldi-Bensouda et al. discussed the impact of allopurinol on the risk of myocardial infarction and compared the drug to colchicine. The myocardial infarction OR in the allopurinol group was 0.80, compared to 1.17 in the colchicine group.

In a critical review, Robert et al. emphasised that the effects
of allopurinol on cardiovascular disease are mediated by XO inhibitors via free radicals and inhibition of oxidative stress. Gladden et al. studied the effect of allopurinol on systolic and diastolic left ventricular function in rats with volume overload from aorto-caval fistula. Allopurinol increased left ventricular (LV) contractility and ejection fraction, but did not alter LV dilation and diastolic pressure/wall stress rate as a measure of diastolic function, despite XO activity being increased in human myocytes with volume overload. The aforementioned data may explain why, in the EXACT-HF study in hyperuricaemic heart failure patients, allopurinol failed to improve LV ejection fraction, symptoms, exercise capacity and time to hospitalisation.

Recently, Valbusa et al. reported an increase in incidence of atrial fibrillation in type 2 diabetes patients with hyperuricaemia (10.5% in 10 years) with an OR of 2.43, but there are insufficient data to confirm that this increase could be prevented by using XO inhibitors. To date, no trial has been conducted to examine the effect of allopurinol on atrial fibrillation.

Beveridge et al. reported that allopurinol was associated with significant functional improvement in older rehabilitation patients, including those with cardiovascular disease. The improvement in functional status was demonstrated using the Barthel score, which was higher in the allopurinol group (4.7 vs 3.6; p = 0.002). These findings could be attributed to the increase in ATP production by allopurinol.

Sanchis-Gomar analysed post-exercise cardiovascular markers of injury in 12 football players. They found that 300 mg allopurinol before a football game had no significant effect on these markers, except for promedulin levels, which were higher in allopurinol before a football game had no significant effect on cardiovascular end-points, composite cardiovascular death, cardiovascular death and hospitalization due to cardiovascular cause, and cardiovascular death and hospitalization due to cardiovascular cause.

Conclusion

XO inhibitors have proven efficacy as second-line drugs in patients with chronic stable ischaemic heart disease, and are recommended in this setting by current evidence-based guidelines. In other manifestations of ischaemic heart disease, data are controversial and further investigation is warranted.

Dr M Zdrenghea was supported by a research grant from the Romanian National Authority for Scientific Research CNCS – UEFISCDI, project number PN-II-ID-PCE 2012-4-0417. Drs D Zdrenghea and D Pop contributed equally to this work.

References

1. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359(17): 1811–1821.
2. Zdrenghea D, Marta D, Constantinescu M, Cucuianu M. Behaviour of uricemia in hyperlipoproteinemic subjects. Med Interna 1980; 18(4): 385–390.
3. Wu SH, Shu XO, Milne G, et al. Uric acid correlates to oxidation and inflammation in opposite directions in women. Biomarkers 2015; 20(4): 225–231.
4. Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart 2013; 99(11): 759–766.
5. Pacher P, Bitkai S, Kinon G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58(3): 389–462.
6. Struthers A, Shearer F. Allopurinol: novel indications in cardiovascular disease. Heart 2012; 98(21): 1543–1556.
7. Sában-Ruiz J, Alonso-Pacho A, Fabregate-Fuente M, de la Puerta González-Quevedo C. Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation. Antinflamm Antiallergy Agents Med Chem 2013; 12(1): 94–99.
8. Agabiti-Rosei E, Grassi G. Beyond gout: uric acid and cardiovascular diseases. Curr Med Res Opin 2013; 29(Suppl 3): 33–39.
9. Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther 2012; 30(4): 217–226.
10. Muir SW, Harrow C, Dawson J, et al. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 2008; 39(12): 3303–3307.
11. Ziga N, Becic F. Allopurinol effect on values of lipid profile fractions in hyperuricemic patients diagnosed with metabolic syndrome. Mater Sociomed 2013; 25(3): 167–169.
12. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 2005; 91(6): 749–753.
13. Antony R, Dargie HJ. Allopurinol for chronic stable angina: old drug, new tricks? Lancet 2010; 375(9732): 2126–2127.
14. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34(38): 2949–3003.
15. Stone MH. Allopurinol: A new anti-ischemic role for an old drug. J Am Coll Cardiol 2011; 58(8): 829–830.
16. Rajendra NS, Ireland S, George J, et al. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 2011; 58(8): 820–828.
17. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375(9732): 2161–2167.
18. Rekhrj S, Gandy SJ, Szewjowski BR, et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol 2013; 61(9): 926–932.
19. Agarwal V, Hans N, Messeri FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2013; 15(6): 435–442.
20. George J, Struthers AD. The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovasc Ther 2008; 26(1): 59–64.
21. Xiao J, She Q, Wang Y, Luo K, Yin Y, Hu R, Huang K. Effect of allopurinol on cardiomyocyte apoptosis in rats after myocardial infarction. Eur J Heart Fail 2009; 11(1): 20–27.
22. Rentoulakos E, Tsarouhas K, Tsimpikou C, et al. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol
Death rates in patients with heart failure is inversely related to the wealth of the country they live in, according to late breaking results from the INTERCHF study, presented recently at Heart Failure 2017 and the 4th World Congress on Acute Heart Failure. 

Death rates in India and Africa were three to four times higher than those documented in Western countries.

‘Heart failure is a common condition that causes morbidity and mortality worldwide’, said lead author Dr Hisham Dokainish, a principal investigator at the Population Health Research Institute (PHRI), McMaster University, Hamilton, Canada.

‘Most data on heart failure have come from Western countries but the majority of the world’s population lives elsewhere’, he continued. ‘This study was conducted to fill large gaps in knowledge about congestive heart failure in non-Western countries.’

The International Congestive Heart Failure (INTERCHF) study was an observational cohort study that enrolled 5 823 patients with heart failure in 16 countries grouped into six regions: Africa (Mozambique, Nigeria, South Africa, Sudan, Uganda), China, India, the Middle East (Egypt, Qatar, Saudi Arabia), south-east Asia (Malaysia, the Philippines), and South America (Argentina, Chile, Colombia and Ecuador).

Data on each patient was collected at baseline, six months and one year, and entered into the electronic data-management system at PHRI. Baseline data included demographics (age, gender), cardiac and non-cardiac factors (previous heart attack or stroke, duration of congestive heart failure, diabetes mellitus, renal failure, chronic obstructive pulmonary disease), medications, socio-economic factors (education level, literacy, employment, urban/rural setting) and heart failure aetiology.

At six months and one year, data were collected on the frequency and cause of any hospitalisations in the previous six months. Information was also recorded on death and cause of death. The investigators calculated death rates in each region and adjusted for 20 variables, which included demographic, clinical, and socio-economic factors, medications and cause of heart failure.

The overall all-cause mortality rate for the entire study population was 17%. It was highest in Africa (34%) and India (23%), intermediate in south-east Asia (15%), and lowest in the Middle East (9%), South America (9%) and China (7%).

Dr Dokainish said: ‘Mortality in patients with heart failure was inversely related to the wealth of the country. The poorer the country, the higher the mortality rate, and the richer the country, the lower the mortality rate.’

‘In Western countries the one-year mortality rate for patients with heart failure is 5–10%, added Dr Dokainish. ‘We’re finding two to three times that death rate in African and Indian patients.’

‘We were very surprised by the much higher mortality rates’, he continued. ‘You could say maybe the patients in Africa or India were sicker, or didn’t take their medicines, or had poorer heart function, but we adjusted for all of those things and don’t really understand why their death rates were so much higher.’

The researchers hypothesised that variables not measured in the study contributed to the high death rates, such as access to and quality of healthcare, and cardiac biomarkers. These variables will be measured in the next phase of the research programme, the Global Congestive Heart Failure (G-CHF) study, which aims to recruit 25 000 heart failure patients from all inhabited continents and income levels. Genetic analyses will also be conducted in a G-CHF sub-study.

Dr Dokainish said: ‘INTERCHF has shown that there are large differences in the risk of heart failure patients dying at one year depending on where they live. We hope to discover why these differences exist through the G-CHF study. If that identifies barriers to receiving care that are due to the way a healthcare system is structured, access to healthcare, or quality of healthcare, then that need to be addressed.’

Source: European Society of Cardiology Press Office